Cyclopropanation of a variety of substituted cinnamyl alcohols with Et2Zn and CH2I2 proceeded in the presence of a catalytic amount of (S)-2-(methanesulfonyl)amino-1-(p-toluenesulfonyl)amino-3-phenylpropane to afford the corresponding cyclopropylmethanols in excellent yields and with moderate to high enantioselectivity (51–86% ee). Highly enantiomerically enriched substituted 2,3-methanocinnamyl alcohols
在催化量的(S)-2-(甲磺酰基)氨基-1-(对甲苯磺酰基)氨基-3-苯基丙烷的催化存在下,用Et 2 Zn和CH 2 I 2进行各种取代的肉桂醇的环丙烷化反应。以优异的收率和中等至高对映选择性(51-86%ee)提供相应的环丙基甲醇。通过将在对映选择性环丙烷化中生成的相应的2,3-甲氧基肉桂醇转化为3,5-二硝基苯甲酸酯衍生物,然后重结晶和水解,可以得到高度对映体富集的取代的2,3-甲氧基肉桂醇(84-97%ee) 。
HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST
申请人:Palle Venkata
公开号:US20090298744A1
公开(公告)日:2009-12-03
Compounds of the present disclosure are fused pyrimidine compounds of formula (I), its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, as Adenosine receptor antagonists.
Processes of their preparation are also described in the disclosure.
Heterocyclic compounds as adenosine receptor antagonist
申请人:Advinus Therapeutics Pvt. Ltd.
公开号:US08252797B2
公开(公告)日:2012-08-28
Compounds of the present disclosure are fused pyrimidine compounds of formula (I), its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, as Adenosine receptor antagonists.
Processes of their preparation are also described in the disclosure.